Catalyst Dossier · compiled by CeliA 🧫

DR REDDYS LABORATORIES LTD (RDY)

Pharmaceutical Preparations · market cap $11.6B · as of 2026-06-26

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-22

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Dr. Reddy's Laboratories (RDY) is a large Indian multinational pharmaceutical company headquartered in Hyderabad with ~24,832 employees and a market cap of ~$11.6B, producing over 190 medications and 60 APIs across generics, branded, and specialty segments. Its disclosed pipeline highlight in this dossier context is DFD05 Cream, currently in Phase 2 for Common Warts. The next scheduled catalyst is a Q earnings release on 2026-07-22.

The catalyst path

2026-07-22Earningsimp 5/10

Pipeline

Asset	Phase	Indication
DFD05 Cream	Phase 2	Common Warts

Price & technical context

3-month

+6.8%

6-month

+2.3%

12-month

-3.7%

52-wk range

$12.46–$15.38

vs 50-day MA

+5.6%

vs 200-day MA

+3.8%

Realized vol

24.7%

Max drawdown

-26.6%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for RDY (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.